By Marie Rosenthal, MS
Saying the benefits no longer outweigh the potential risks, the FDA revoked the emergency use authorization (EUA) for hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) to treat COVID-19.
The EUA allowed hydroxychloroquine and chloroquine to be donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. The agency